Human Therapeutic Organoid Core
The Weill Cornell Medicine Human Therapeutic Organoid Core (HTOC) facility serves as a central facility for human organoid technology to accelerate organoid-based scientific discovery. Organoids are mini-organs in a dish, made up of cells that self-organize and can more accurately recapitulate human biology. Human organoid technology has arisen as one of the best models to study human development and disease. Organoids hold great promise to revolutionize healthcare with multimodal potential for new drug development, precision medicine, and regenerative medicine.
The HTOC facility will provide human embyronic stem cell (hESC) derived as well as tissue derived organoids as a fee-for-service. HTOC primarily focuses on sc-islet organoids. The central facility will overcome the technical challenges of quality control and reproducibility often found when using organoid technologies. HTOC also provides consultation services and hands-on training in organoid technology, as well as human organoid QC analyses. For more information, please visit our website: https://research.weill.cornell.edu/core-facilities/human-therapeutic-organoid-core
Contact Information
Core Director: Qiao Joe Zhou , Ph.D.
Email: jqz4001@med.cornell.edu
Core Managing Director: Lauretta A. Lacko Ph.D
Email: lal2018@med.cornell.edu
